Overview

* Bio-Rad Q3 2025 revenue grows 0.5%, beating analyst expectations, per LSEG data

* Adjusted EPS for Q3 2025 beats analyst estimates, reflecting effective cost management

* Company reports net loss due to fair market value change in Sartorius AG investment

Outlook

* Bio-Rad ( BIO/B ) maintains full-year 2025 revenue growth forecast at 0 to 1.0%

* Company expects 2025 non-GAAP operating margin of 12.0 to 13.0%

Result Drivers

* COST MANAGEMENT - Disciplined cost management contributed to better-than-expected operating margins

* FUNDING CHALLENGES - Reduced demand for instruments due to constrained academic research and biotech funding environment

* DIABETES TESTING RATES - Lower reimbursement rates for diabetes testing in China impacted Clinical Diagnostics sales

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Sales Beat $653 mln $651.80

mln (5

Analysts

)

Q3 Beat $2.26 $1.95 (5

Adjusted Analysts

EPS )

Q3 EPS -$12.70

Q3 Net -$341.90

Income mln

Q3 Gross 52.60%

Margin

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

* Wall Street's median 12-month price target for Bio Rad Laboratories Inc ( BIO/B ) is $325.00, about 1.7% below its October 28 closing price of $330.42

* The stock recently traded at 33 times the next 12-month earnings vs. a P/E of 27 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)